Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer

Kazuhiro Suzuki, Shoji Nagao, Takashi Shibutani, Kasumi Yamamoto, Tomoatsu Jimi, Hiroko Yano, Miho Kitai, Takaya Shiozaki, Kazuko Matsuoka, Satoshi Yamaguchi

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)

Abstract

Objective: We evaluated the efficacy and safety of the combination of paclitaxel, carboplatin, and bevacizumab in patients with advanced or recurrent cervical cancer. Methods: Subjects included patients with advanced or recurrent cervical cancer not amenable to curative treatment with surgery or radiation therapy. Treatment consisted of paclitaxel 175 mg/m2, carboplatin area under the curve 6 mg/mL/min, and bevacizumab 15 mg/kg every 21 days until disease progression, complete remission, or limiting toxicity. The primary endpoint was the objective response. Results: In total, 34 patients received a median of 6 treatment cycles (range 2–25). The median follow-up period was 18.5 months (range 2–29). The objective response was 88% (95% confidence interval: 72.5%–96.7%). Seventeen patients (50%) experienced complete response, whereas 13 patients experienced (38%) partial response with a median duration of 6 months. Grades 3 and 4 hematologic toxicities manifested as neutropenia in 14 (41.2%), leukopenia in 14 (41.2%), anemia in 11 (32.4%), and thrombocytopenia in 9 (26.5%) patients. One patient who underwent prior pelvic irradiation developed grade 2 rectovaginal fistula. Conclusion: The combination of paclitaxel, carboplatin, and bevacizumab is effective and safe in patients with advanced or recurrent cervical cancer.

Original languageEnglish
Pages (from-to)554-557
Number of pages4
JournalGynecologic Oncology
Volume154
Issue number3
DOIs
Publication statusPublished - Sep 2019
Externally publishedYes

Keywords

  • Bevacizumab
  • Carboplatin
  • Cervical cancer
  • Paclitaxel

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Fingerprint

Dive into the research topics of 'Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer'. Together they form a unique fingerprint.

Cite this